The FDA cleared closely-held Candesant Biomedical’s Brella, the first and only three-minute SweatControl Patch for the reduction of excessive underarm sweating in adults with primary axillary hyperhidrosis.
Brella uses Candesant’s novel, patented TAT (targeted alkali thermolysis) technology. The Brella three-minute SweatControl Patch provides a new in-office approach to sweat control that is fast, non-invasive, needle-free, aluminum-free, and affordable, with results lasting three-to-four months.
“FDA clearance of Brella represents a significant advance for millions of people dealing with the physical, emotional, financial, and aesthetic impact of hyperhidrosis, or sweating beyond what’s needed to keep the body cool,” Niquette Hunt, founder and CEO of Candesant, said in a statement.
“Satisfaction with current treatments is low and 80% of consumers are seeking new treatments to manage excessive underarm sweat,” she added.
